Innovative, implantable, combination drug+device products that utilize novel biomaterials. TYRX\'s first commercially available products include the AIGISRx(R) Antibacterial Envelope & Flat Sheet technologies, designed to reduce surgical-site infections associated with Cardiac Implantable Electronic Devices (CIEDs).
Start Trial Get Full Profile
There’s no risk. Start your trial today to see profiles of TYRX (Acquired) plus 4858 other startups.